Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 4/20 | 0.40 |
| ▸ | OGA | O60502 | 2/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | GABRP | O00591 | 2/20 | 0.36 |
| ▸ | GABRD | O14764 | 2/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.36 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.36 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.36 |
| ▸ | GABRE | P78334 | 2/20 | 0.36 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.36 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.36 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.36 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.36 |
| ▸ | NNMT | P40261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30434221 | 1.00 | GABRA5 (0.40) | GABRA5OGANOS3NOS2GABRP | |
| SCHEMBL17298724 | 0.82 | NOS3 (0.40) | GABRA5NOS3NOS2GABRPGABRD | |
| SCHEMBL17055342 | 0.82 | OGA (0.40) | GABRA5OGANOS3NOS2GABRP | |
| SCHEMBL23361675 | 0.79 | NOS3 (0.38) | GABRA5OGANOS3NOS2GABRP | |
| SCHEMBL21949396 | 0.79 | ALOX5AP (0.38) | GABRA5OGANOS3NOS2GABRP | |
| SCHEMBL19283986 | 0.78 | WDR91 (0.40) | GABRA5OGASMN1; SMN2KDM4EWDR91 | |
| SCHEMBL31572560 | 0.78 | WDR91 (0.40) | GABRA5OGASMN1; SMN2KDM4EWDR91 | |
| SCHEMBL31419339 | 0.75 | GABRA5 (0.41) | GABRA5OGAWDR91SLC22A12PIK3CA | |
| SCHEMBL3644606 | 0.74 | WDR91 (0.41) | SMN1; SMN2KDM4EWDR91SLC22A12ALDH1A1 | |
| SCHEMBL13543769 | 0.73 | PIK3CA (0.42) | OGANOS3NOS2KDM4EPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111542523-B | Heterocyclic compounds as PRMT5 inhibitors | 朱比连特埃皮斯科瑞有限责任公司 | 2024-03-29 | — | — | CN | disclosed |
| EP-3704120-B1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | JUBILANT EPISCRIBE LLC (US) | 2024-03-06 | — | — | EP | disclosed |
| CN-113735836-B | Pyridazine compound and application thereof | 江苏先声药业有限公司 | 2023-05-30 | — | — | CN | disclosed |
| US-11459338-B2 | Heterocyclic compounds as PRMT5 inhibitors | JUBILANT EPISCRIBE LLC (US) | 2022-10-04 | — | — | US | disclosed |
| US-20220002267-A1 | TYROSINE KINASE 2 INHIBITORS, PREPARATION METHODS AND MEDICINAL USES THEREOF | Eternity Bioscience Inc. | 2022-01-06 | — | — | US | disclosed |
| CN-113735836-A | Pyridazine compound and application thereof | 江苏先声药业有限公司 | 2021-12-03 | — | — | CN | disclosed |
| US-20210371431-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | JUBILANT EPISCRIBE LLC | 2021-12-02 | — | — | US | disclosed |
| US-20210371431-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | JUBILANT EPISCRIBE LLC | 2021-12-02 | — | — | US | disclosed |
| EP-3704120-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | Jubilant Episcribe LLC (US) | 2020-09-09 | — | — | EP | disclosed |
| CN-111542523-A | Heterocyclic compounds as PRMT5 inhibitors | 朱比连特埃皮斯科瑞有限责任公司 | 2020-08-14 | — | — | CN | disclosed |
| WO-2019102494-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | JUBILANT BIOSYS LIMITED (IN) | 2019-05-31 | — | — | WO | disclosed |
| WO-2019102494-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | JUBILANT BIOSYS LIMITED (IN) | 2019-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220002267-A1 | TYROSINE KINASE 2 INHIBITORS, PREPARATION METHODS AND MEDICINAL USES THEREOF | TYK2, ABL1, PTK2B | GABRA5 1781/4885OGA 2228/4885NOS3 2863/4885 |
| US-11459338-B2 | Heterocyclic compounds as PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | GABRA5 1041/4885OGA 3670/4885NOS3 766/4885 |
| US-20210371431-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | GABRA5 1041/4885OGA 3670/4885NOS3 766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.